| Literature DB >> 25309595 |
Yi-Der Jiang1, Lee-Ming Chuang2, Dee Pei3, Yann-Jinn Lee4, Jun-Nan Wei5, Fung-Chang Sung6, Tien-Jyun Chang1.
Abstract
To investigate the role of E23K polymorphism of the KCNJ11 gene on early onset of type 2 diabetes in school-aged children/adolescents in Taiwan, we recruited 38 subjects with type 2 diabetes (ages 18.6 ± 6.6 years; body mass index percentiles 83.3 ± 15.4) and 69 normal controls (ages 17.3 ± 3.8 years; body mass index percentiles 56.7 ± 29.0) from a national surveillance for childhood/adolescent diabetes in Taiwan. We searched for the E23K polymorphism of the KCNJ11 gene. We found that type 2 diabetic subjects had higher carrier rate of E23K polymorphism of KCNJ11 gene than control subjects (P = 0.044). After adjusting for age, gender, body mass index percentiles, and fasting plasma insulin, the E23K polymorphism contributed to an increased risk for type 2 diabetes (P = 0.047). K23-allele-containing genotypes conferring increased plasma insulin level during OGTT in normal subjects. However, the diabetic subjects with the K23-allele-containing genotypes had lower fasting plasma insulin levels after adjustment of age and BMI percentiles. In conclusion, the E23K variant of the KCNJ11 gene conferred higher susceptibility to type 2 diabetes in children/adolescents. Furthermore, in normal glucose-tolerant children/adolescents, K23 allele carriers had a higher insulin response to oral glucose loading.Entities:
Year: 2014 PMID: 25309595 PMCID: PMC4189766 DOI: 10.1155/2014/983016
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Clinical and metabolic features between normal controls and type 2 diabetic subjects in the present study.
| Non-DM ( | DM ( |
| |
|---|---|---|---|
| Age (years) | 17.3 ± 3.8 | 18.6 ± 6.6 | 0.289 |
| BMI percentiles | 56.7 ± 29.0 | 83.8 ± 15.4 | <0.001 |
| Glucose (mmol/L) | 5.19 ± 0.40 | 10.65 ± 4.05 | <0.001 |
| TCH (mmol/L) | 4.05 ± 0.77 | 4.22 ± 1.02 | 0.4159 |
| TG (mmol/L) | 0.74 ± 0.26 | 1.17 ± 0.45 | 0.0005 |
| HDL (mmol/L) | 1.43 ± 0.39 | 1.20 ± 0.50 | 0.0320 |
| Fasting insulin (pmol/L) | 7.66 ± 4.47 | 17.99 ± 20.43 | 0.0043 |
| HOMA-IR | 1.78 ± 1.06 | 7.48 ± 8.09 | <0.001 |
| Log (HOMA-IR) | 0.402 ± 0.624 | 1.449 ± 1.143 | <0.001 |
| HOMA-B | 94.62 ± 58.17 | 94.13 ± 168.52 | 0.987 |
| Log (HOMA-B) | 4.372 ± 0.625 | 3.490 ± 1.458 | 0.001 |
| Sex (M : F) | 26 : 43 | 20 : 18 | 0.157$ |
*P value with Student's t-test.
$By chi-squared test.
BMI percentiles: body mass index age- and sex-specific percentiles; TCH: total cholesterol; TG: triglyceride; HDL: high density lipoprotein-cholesterol; HOMA-IR: homeostasis model assessment-insulin resistance; HOMA-B: homeostasis model assessment-β cell.
Genotypic distribution of E23K polymorphism of the Kir6.2 between normal control and type 2 diabetes subjects.
| Non-DM ( | DM ( |
| Odds ratio | 95% confidence interval | |
|---|---|---|---|---|---|
| Genotype∗ | |||||
| EE, | 24 (34.8%) | 6 (15.8%) | |||
| EK/KK, | 45 (65.2%) | 32 (84.2%) | 0.044 | 2.84 | 1.04–7.75 |
| Allele | |||||
| E-allele, | 81 (58.7%) | 38 (50.0%) | |||
| K-allele, | 57 (41.3%) | 38 (50.0%) | 0.251 | 1.42 | 0.81–2.50 |
*Chi-squared test.
Logistic regression analysis with type 2 diabetic status as dependent variables, age, sex, BMI age- and sex-specific percentiles, and genotype of E23K polymorphism in Kir6.2 as independent variables.
| Independent variables | Odds ratio | 95% CI |
|
|---|---|---|---|
| Model 1 | |||
| EK/KK versus EE | 2.941 | 0.764–11.323 | 0.117 |
| Age (every 1 year increment) | 1.156 | 0.920–1.454 | 0.214 |
| Sex (male = 1, female = 2) | 0.672 | 0.224–2.019 | 0.479 |
| BMI age- and sex-specific percentiles (every 1 percentile increment) | 1.060 | 1.027–1.094 |
|
| Model 2 | |||
| EK/KK versus EE | 4.105 | 1.0008–16.831 |
|
| Age (every 1 year increment) | 1.240 | 0.960–1.601 | 0.099 |
| Sex (male = 1, female = 2) | 0.826 | 0.252–2.711 | 0.752 |
| BMI age- and sex-specific percentiles (every 1 percentile increment) | 1.047 | 1.014–1.080 |
|
| Fasting plasma insulin levels (every 1 pmol/L increment) | 1.066 | 1.001–1.135 |
|
Figure 1Glucose and insulin homeostasis during OGTT in the normal glucose-tolerant subjects according to genotypes of the KCNJ11 gene. There was no significant difference in plasma glucose levels in subjects with EE genotype compared with those with K23-allele-containing genotypes (EK or KK) (a). Subjects with EK/KK genotypes tended to have a higher level of plasma insulin level during OGTT (b). ∗ indicates significant difference between the two groups.
Clinical and metabolic features between those with E/E genotype and K-containing allele among type 2 diabetic and nondiabetic subjects, respectively.
| Type 2 diabetic subjects | Nondiabetic subjects | |||||
|---|---|---|---|---|---|---|
| Genotypes | E/E ( | E/K + K/K ( |
| E/E ( | E/K + K/K ( |
|
| Sex (M : F) | 4 : 2 | 16 : 16 | 0.663$ | 11 : 13 | 15 : 30 | 0.434$ |
| Age (years) | 21.5 ± 9.7 | 18.0 ± 5.8 | 0.242 | 17.2 ± 3.3 | 17.4 ± 4.1 | 0.861 |
| BMI age- sex-specific percentiles | 84.02 ± 22.07 | 83.73 ± 14.31 | 0.970 | 56.65 ± 25.63 | 56.79 ± 30.87 | 0.987 |
| Glucose (mmol/L) | 10.0 ± 3.8 | 10.8 ± 4.1 | 0.715 | 5.1 ± 0.4 | 5.2 ± 0.4 | 0.133 |
| Fasting plasma insulin levels (pmol/L) | 237.21 ± 230.48 | 112.18 ± 126.24 | 0.076 | 52.2 ± 31.1 | 56.5 ± 32.8 | 0.602 |
| Ins-30′ | — | — | 414.67 ± 53.23 | 582.09 ± 94.71 | 0.222 | |
| Ins-60′ | — | — | 381.81 ± 51.51 | 671.57 ± 132.39 |
| |
| Ins-90′ | — | — | 379.09 ± 55.41 | 545.79 ± 107.51 | 0.280 | |
| Ins-120′ | — | — | 268.32 ± 48.95 | 375.18 ± 67.10 | 0.283 | |
| AUC-glucose | — | — | 832.92 ± 21.83 | 855.72 ± 17.02 | 0.422 | |
| AUC-insulin | 40074.46 ± 4153.74 | 60457.87 ± 10721.20 | 0.180 | |||
| HOMA-B | 127.0 ± 194.8 | 89.89 ± 168 | 0.685 | 97.69 ± 70.03 | 92.98 ± 51.55 | 0.751 |
*P value with Student's t-test.
$ P value with Fisher's exact test.